AT&T Inc. (T) Stock Price Today
Replimune's melanoma drug gets FDA nod but faces legal probe over data practices
Replimune Group's melanoma drug Tudriqev received accelerated FDA approval after two prior rejections, based on a 24.20% response rate in trials. Following this, BMO Capital raised its price target for Replimune stock from $16 to $20, indicating stro...
Digital Realty backs Texas Governor Abbott's plan for responsible data center growth amid rising AI demand.
Digital Realty, the largest cloud- and carrier-neutral data center platform, supports Texas Governor Abbott's initiative for responsible and transparent data center investment in Texas. The company emphasizes collaboration with officials and communit...
Verisk Analytics CEO Lee Shavel sells 2,500 shares for $550,000.
Verisk Analytics CEO Lee Shavel has sold 2,500 shares of the company, generating $550,000 from the transaction. This sale may indicate personal portfolio adjustments or strategic financial planning by the CEO. Investors might watch for any further in...
Replimune's stock jumps after FDA approves its first skin cancer drug Tudriqev
Replimune Group Inc. received FDA approval for Tudriqev, its first drug targeting a difficult form of skin cancer, marking a major milestone for the biotech company. Despite earlier rejections and concerns over clinical data quality, the FDA granted ...
Man Group PLC discloses 0.57% stake in Bodycote Plc, reducing long equity swap positions.
Man Group PLC has publicly disclosed holding a 0.57% interest in Bodycote Plc as of August 6, 2026. The disclosure reveals that Man Group is reducing its long positions through multiple equity swap transactions at varying prices. This update is part ...
Class action lawsuit filed against Replimune over undisclosed FDA study issues and misleading statements.
A class action lawsuit has been filed against Replimune Group, Inc. alleging the company failed to disclose critical issues related to its FDA Biologics License Application (BLA). The lawsuit claims Replimune did not address FDA concerns about study ...
FDA panel to review GRAIL's Galleri blood test for early multi-cancer detection on Sept 23, 2026
GRAIL announced that the FDA's advisory panel will meet on September 23, 2026, to review the Premarket Approval application for its Galleri blood test, designed to detect multiple cancers early by identifying cancer-specific methylation patterns. The...
Class action lawsuit filed against Replimune over alleged misleading FDA data disclosures
A class action lawsuit has been filed against Replimune Group, alleging the company made false or misleading statements and failed to disclose critical issues related to its Biologics License Application (BLA). The suit claims Replimune did not addre...
Gold miner ETFs like XGD track gold prices but face caution amid inflation and Fed policy uncertainty.
The iShares S&P/TSX Global Gold Index ETF (XGD) tracks major gold miners such as Barrick, Newmont, and Agnico, making its performance closely tied to gold prices. Currently, gold miner ETFs including XGD are influenced by speculative factors like geo...
Progyny CEO to present at Canaccord Genuity Annual Growth Conference on Aug 11, 2026
Progyny, Inc., a leader in women's health and family building solutions, announced that CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026. The presentation will be webcast live and avail...
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.